by synergycap1 | Jul 18, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
With the failure of the Republicans’ health-care bill, the market is wondering if the GOP can get tax reform done — but there could be a “win” still to come for politicians and Wall Street, expert Michael Farr told CNBC on Tuesday. “There...
by synergycap1 | Jul 18, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Working Capital
The new carrier will start with Denver nonstop, add three more cities by spring.
by synergycap1 | Jul 18, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Finance, Non-Bank Loans, Working Capital
Rio de Janeiro was home to the Americas’ largest slave port, which received nearly a million slaves over several centuries. Now modern day Cariocas have developed an app that provides an immersive tour through that history.
by synergycap1 | Jul 18, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
IBM stock was down 2 percent on Tuesday after it disclosed earnings for the second quarter of the year, falling short of revenue estimates but beating earnings estimates. The company will start its call with financial analysts at 5 p.m. Eastern time. EPS: Excluding...
by synergycap1 | Jul 18, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Finance, Grow, Working Capital
Peter Drucker is often quoted saying that “the purpose of business is to get customers.” That thinking has evolved slightly. Today, the purpose of business it to get customers that get you even more customers. Loyalty is still important, but loyalty by...
by synergycap1 | Jul 18, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
Vertex Pharmaceuticals said Tuesday that its three-drug cocktails improved a measure of lung function in patients with cystic fibrosis by 9.6 percentage points or more, surpassing Wall Street’s expectations and setting the company up to advance a medicine to...
